Altimmune is a biotechnology business based in the US. Altimmune shares (ALT) are listed on the NASDAQ and all prices are listed in US Dollars. Altimmune employs 52 staff and has a market cap (total outstanding shares value) of 0.00.
Finder Award
SoFi Invest
Finder Award
eToro
tastytrade
| Latest market close | $2.70 |
|---|---|
| 52-week range | $2.34 - $17.17 |
| 50-day moving average | $2.89 |
| 200-day moving average | $7.24 |
| Wall St. target price | $19.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.70 |
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.7 from 2023-09-20
| 1 week (2023-09-14) | -3.23% |
|---|---|
| 1 month (2023-08-21) | 5.47% |
| 3 months (2023-06-21) | -35.56% |
| 6 months (2023-03-21) | -45.45% |
| 1 year (2022-09-21) | -78.72% |
|---|---|
| 2 years (2021-09-21) | -82.05% |
| 3 years (2020-09-21) | 13.57 |
| 5 years (2018-09-21) | 26.19 |
| Operating margin TTM | 108162.96% |
|---|---|
| Gross profit TTM | $-70,520,000 |
| Return on assets TTM | -27.85% |
| Return on equity TTM | -44.89% |
| Profit margin | 0% |
| Book value | $3.19 |
| Market Capitalization | $153.8 million |
TTM: trailing 12 months
We're not expecting Altimmune to pay a dividend over the next 12 months.
Altimmune's shares were split on a 1:30 basis on 13 September 2018. So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Altimmune shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for Altimmune shares which in turn could have impacted Altimmune's share price.
Over the last 12 months, Altimmune's shares have ranged in value from as little as $2.34 up to $17.17. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Altimmune's is -0.0411. This would suggest that Altimmune's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Altimmune has bucked the trend.
Altimmune, Inc. , a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015.
Everything we know about the Discord IPO, plus information on how to buy in.
We’ve pulled a list together of the meme stocks being mentioned most on Reddit in the past 24 hours.
Steps to owning and managing TOTA, with 24-hour and historical pricing before you buy.
Steps to owning and managing TOT, with 24-hour and historical pricing before you buy.
Steps to owning and managing THBR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBE, with 24-hour and historical pricing before you buy.
Steps to owning and managing TEF, with 24-hour and historical pricing before you buy.
Steps to owning and managing PSACU, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNK, with 24-hour and historical pricing before you buy.
Steps to owning and managing IPHA, with 24-hour and historical pricing before you buy.